Manel Esteller (Sant Boi de Llobregat, Barcelona, Catalonia, Spain, 1968) graduated in Medicine from the Universidad de Barcelona in 1992, where he also obtained his Ph.D. degree specialising in molecular genetics of endometrial carcinoma, in 1996. He was an Invited Researcher at the School of Biological and Medical Sciences at the University of St. Andrews, (Scotland, UK) during which time his research interests focused on the molecular genetics of inherited breast cancer. From 1997 to 2001, Esteller was a Postdoctoral Fellow and a Research Associate at the Johns Hopkins University and School of Medicine, (Baltimore, USA) where he studied DNA methylation and human cancer. His work was decisive in establishing promoter hypermethylation of tumour suppressor genes as a common hallmark of all human tumours. From October 2001 to September 2008 Manel Esteller was the Leader of the CNIO Cancer Epigenetics Laboratory, where his principal area of research were the alterations in DNA methylation, histone modifications and chromatin in human cancer. Since October 2008 until May 2019, Dr Esteller has been the Director of the Cancer Epigenetics and Biology Program (PEBC) in Barcelona. He is the Director of the Josep Carreras Leukaemia Research Institute (IJC), Chairman of Genetics in the School of Medicine of the University of Barcelona, and an ICREA Research Professor. His current research is devoted to the establishment of the epigenome and epitranscriptome maps of normal and transformed cells, the study of the interactions between epigenetic modifications and non-coding RNAs, and the development of new epigenetic drugs for cancer therapy. Author of more than 600 original publications in peer-reviewed scientific journals, 24 of them categorized as “Highly Cited Paper”. Dr Esteller has the highest total impact factor and the highest number of citations among biomedical scientists performing their research in Spain, having an h-Index of 130 by Web of Science – Clarivate Analytics and a h-Index of 156 according to Google Scholar. Dr. Esteller is considered among the Top 0.01% of World Scientists based on Impact by both the Stanford University (METRICS) and the Web of Science Group-Clarivate Analytics. He is also a Member of numerous international scientific societies, Editorial Boards and reviewer for many journals and funding agencies. Dr Esteller is also Associate Editor for Cancer Research, The Lancet Oncology, Carcinogenesis, Genome Research and The Journal of The National Cancer Institute. He is the Editor-in-Chief of Epigenetics. He is also the director of The Cancer Genome Atlas (TCGA) project for Cancer of Unknown Primary (CUP) of the National Cancer Institute - National Institutes of Health (NCI-NIH) in the United States (US).
Manel Esteller has not published a dataset on rdl-hub yet. Their raw data, if attached to any publication, appears in Publications.
